The article discusses the molecular alterations in advanced non-small cell lung cancer (NSCLC), emphasizing the importance of identifying oncogenic drivers for personalized treatment. Over the past two decades, significant progress has been made in identifying and targeting molecular alterations, with approximately 60% of lung adenocarcinoma patients in Western populations and 80% in Asian populations having targetable molecular alterations. These alterations are more common in non-smokers, east Asians, and younger patients. The current landscape of druggable molecular targets includes EGFR, ALK, BRAF, ROS1, KRAS, HER2, MET, NTRK, RET, and NRG1, with additional targets like PI3K and FGFR gaining attention. Next-generation sequencing (NGS) is crucial for identifying these alterations and understanding resistance mechanisms. The article highlights the importance of NGS in diagnosing NSCLC and the challenges in implementing molecular testing, with over 60% of responders believing it is performed in fewer than 50% of patients. Liquid biopsies and circulating tumor DNA (ctDNA) are being explored as alternatives to tissue biopsies. The article also discusses the development of targeted therapies for various oncogenic drivers, including EGFR, HER2, and KRAS, with recent advancements in third-generation EGFR inhibitors like osimertinib and fourth-generation inhibitors. The article concludes with the ongoing research into new therapies for KRAS and ALK mutations, emphasizing the need for continued innovation in the field of precision medicine.The article discusses the molecular alterations in advanced non-small cell lung cancer (NSCLC), emphasizing the importance of identifying oncogenic drivers for personalized treatment. Over the past two decades, significant progress has been made in identifying and targeting molecular alterations, with approximately 60% of lung adenocarcinoma patients in Western populations and 80% in Asian populations having targetable molecular alterations. These alterations are more common in non-smokers, east Asians, and younger patients. The current landscape of druggable molecular targets includes EGFR, ALK, BRAF, ROS1, KRAS, HER2, MET, NTRK, RET, and NRG1, with additional targets like PI3K and FGFR gaining attention. Next-generation sequencing (NGS) is crucial for identifying these alterations and understanding resistance mechanisms. The article highlights the importance of NGS in diagnosing NSCLC and the challenges in implementing molecular testing, with over 60% of responders believing it is performed in fewer than 50% of patients. Liquid biopsies and circulating tumor DNA (ctDNA) are being explored as alternatives to tissue biopsies. The article also discusses the development of targeted therapies for various oncogenic drivers, including EGFR, HER2, and KRAS, with recent advancements in third-generation EGFR inhibitors like osimertinib and fourth-generation inhibitors. The article concludes with the ongoing research into new therapies for KRAS and ALK mutations, emphasizing the need for continued innovation in the field of precision medicine.